InMed Pharmaceuticals, a Phase 1 developing cannabinoid-based products, filed on Friday with the SEC to raise up to $12 million in an initial public offering. The company is currently is listed on the TSX under the symbol IN and on the OTCQX under the symbol IMLFF.
InMed Pharmaceuticals is developing an API using a synthetic cannabinoid named cannabinol, or CBN, and plans to develop its two products INM-755 for rare skin disease Epidermolysis Bullosa (EB) and INM-088 for glaucoma. INM-755 is currently in a Phase 1 trial in The Netherlands.
The Vancouver, Canada-based company was founded in 2014 and plans to list on the Nasdaq under the symbol INM. Roth Capital is the sole bookrunner on the deal. No pricing terms were disclosed.
